Why is Macrogenics (MGNX) Stock Down 28% Today?
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Macrogenics stock is down on Wednesday after MGNX investors learned that the company is discontinuing a Phase 2 clinical trial.
The post Why is Macrogenics (MGNX) Stock Down 28% Today? appeared first on InvestorPlace.
More From InvestorPlace